Agomelatine
| Agomelatine | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 243.30 g/mol [1] |
| Solubility | ~0.5 mg/ml in 1:1 EtOH:PBS (pH 7.2); ~30 mg/ml in EtOH, DMF & DMSO [1] |
| Predicted LogP | 2.7 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C15H17NO2 |
| IUPAC name | N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide |
| SMILES | CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC |
| InChI | InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17) |
| InChIKey | YJYPHIXNFHFHND-UHFFFAOYSA-N |
| CAS number | 138112-76-2 |
| UNII | 137R1N49AD |
| PubChem CID | 82148 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 1–2 hours |
| Metabolism | Liver (90% CYP1A2 and 10% CYP2C9) |
| Excretion | Kidney (80%, mostly as metabolites) |
| Routes of administration | By mouth |
| Dependence liability | Low[3] |
Agomelatine (also known as Thymanax, Valdoxan, S-20098, Agomelatina, Ago-178, S 20098, N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide, agomelatinum, Ago178 or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide) is a substance of the phenethylamine class.
Chemistry
Stereochemistry []
Agomelatine is achiral.
Druglikeness
Lipinski's rule of five
Agomelatine matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- antidepressants (N06A)
- other antidepressants (N06AX)
- (N06AX22)
- agomelatine (N06AX22)
MeSH Classification
- hypnotics and sedatives (M0010885)
Mechanism of action []
The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors. [1]
Medical side effects []
57 side effects listed on drug labels in SIDER 4.1 (agomelatine).
- Eczema
- Paraesthesia
- Pruritus
- Urticaria
- Vision blurred
- Hepatitis
- Rash erythematous
- Abdominal pain
- Gastrointestinal pain
- Aggression
- Angioedema
- Anxiety
- Back pain
- Mental disorder
- Infection
- Connective tissue disorder
- Constipation
- Depression
- Diarrhoea
- Dizziness
- Dyspepsia
- Eye disorder
- Asthenia
- Fatigue
- Gastrointestinal disorder
- Hallucination
- Headache
- Hyperhidrosis
- Influenza
- Irritability
- Jaundice
- Nasopharyngitis
- Nausea
- Nervous system disorder
- Nightmare
- Restless legs syndrome
- Tinnitus
- Tremor
- Vertigo
- Vomiting
- Weight increased
- Weight decreased
- Dry mouth
- Hepatic failure
- Agitation
- Migraine
- Blood alkaline phosphatase increased
- Skin disorder
- Abnormal dreams
- Hypomania
- Hepatobiliary disease
- Mania
- Suicidal ideation
- Face oedema
- Infestation
- Insomnia
- Somnolence
Indications
- Major depression
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 82148, Agomelatine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/82148
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Agomelatine. UNII: 137R1N49AD. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/137R1N49AD
Kim HK, Yang KI. Melatonin and melatonergic drugs in sleep disorders. Translational and Clinical Pharmacology. December 2022; 30(4):163–171. PMID 36632077. https://doi.org/10.12793/tcp.2022.30.e21
Valdoxan Product Information. TGA eBusiness Services. 2013-09-23. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07273-3
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-04-04. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Valdoxan 25 mg film-coated tablets - Summary of Product Characteristics (SmPC). (emc). 13 July 2020. https://www.medicines.org.uk/emc/product/6564/smpc
Thymanax EPAR. European Medicines Agency (EMA). 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/thymanax
Valdoxan EPAR. European Medicines Agency (EMA). 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 19:00:43 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 19:00:39 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 19:00:39 |
| gsrs | ok | 2026-11-20 19:00:39 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015636) | 2026-11-20 19:00:39 |
| kegg | ok | 2026-11-20 19:00:40 |
| pubchem | ok | 2026-11-20 19:00:38 |
| missing (no r/tripreports posts mention it) | 2026-11-20 19:00:39 | |
| sider | ok | 2026-11-20 19:00:39 |
| structure | ok | 2026-11-20 19:00:39 |
| wikipedia | ok | 2026-11-20 19:00:39 |